Format

Send to

Choose Destination
Nanomedicine (Lond). 2014 Dec;9(17):2625-38. doi: 10.2217/nnm.14.197.

A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response.

Author information

1
Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, Copenhagen S, Denmark.

Abstract

AIM:

To combine the dimethyldioctadecyl ammonium/monomycoloyl glycerol (DDA/MMG) liposomal vaccine adjuvant with the Toll-like receptor (TLR) ligands poly(I:C) (TLR3), flagellin (TLR5) or CpG oligodeoxynucleotide 1826 (TLR9) and investigate their physicochemical properties as well as their CD4(+) T-cell-inducing capacity.

MATERIALS & METHODS:

Formulations were investigated by dynamic light scattering and differential scanning calorimetry. Their CD4(+) T-cell induction with a tuberculosis antigen was analyzed by multiplex cytokine analysis, ELISA and intracellular cytokine staining.

RESULTS:

DDA/MMG/CpG was the best combination for obtaining increased CD4(+) T-cell responses. However, coformulating CpG and DDA/MMG liposomes led to instability and the formulation was therefore optimized systematically using a design of experiment.

CONCLUSION:

The nanoparticulate DDA/MMG/CpG adjuvant can be stabilized and synergistically enhances CD4(+) T-cell responses compared with DDA/MMG liposomes.

KEYWORDS:

CD4+ T cells; CpG; adjuvant; cationic liposome; pattern-recognition receptors

PMID:
25529567
DOI:
10.2217/nnm.14.197
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center